Researchers from Philadelphia-based Jefferson Health used an immunotherapy called Car-T cell therapy, which effectively eliminated metastatic CRC in mice.
Car-T immunotherapy involves removing a patient’s immune cells and reengineering them to target only the tumor. They then multiple the cells enmass and inject them back into the patient.
The cells specifically react to a tumor antigen called GUCY2C. The antigen is a potential biomarker and therapeutic agent.
In the study, researchers tested a human-ready version of the therapy on mice. All the mice survived with no side effects during the 75-day observation period.
They replicated the study in mice with CRC with lung metastases and discovered the therapy was equally successful. The mice survived more than 100 days with no metastases.
More articles on gastroenterology:
Task force releases intraocular surgical instrument sterilization guidelines for ASCs — 5 key insights
Demand more: What GI physicians should expect from their pathology lab
The payment shift: patients as payers
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
